Orbimed Advisors LLC bought $16M of ADRX
director, owner at ADARx Pharmaceuticals, Inc.. 950,000 shares at an average of $17.00, traded Sep 28, 2026, filed Sep 30, 2026.
Score components
- +15RoleDirector
- +25Trade size$16.1M at market
- +3Relative to holdingsHoldings up 7%
- 0Price contextNo price history yet
- +15Cluster5 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000947871-26-000910, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 28, 2026 | CConversion Common Stockindirect: See footnotes | +10,690,530 | - | - | 10,690,530 | 12 d ago |
| Sep 28, 2026 | CConversion Common Stockindirect: See footnotes | +2,000,962 | - | - | 12,691,492 | 12 d ago |
| Sep 28, 2026 | CConversion Common Stockindirect: See footnotes | +769,601 | - | - | 13,461,093 | 12 d ago |
| Sep 28, 2026 | CConversion Common Stockindirect: See footnotes | +564,187 | - | - | 14,025,280 | 12 d ago |
| Sep 28, 2026 | POpen-market purchase Common Stockindirect: See footnotes | +300,249 | $17.00 | $5.1M | 14,325,529 | 12 d ago |
| Sep 28, 2026 | CConversion Common Stockindirect: See footnotes | +7,127,019 | - | - | 7,127,019 | 12 d ago |
| Sep 28, 2026 | CConversion Common Stockindirect: See footnotes | +1,333,975 | - | - | 8,460,994 | 12 d ago |
| Sep 28, 2026 | CConversion Common Stockindirect: See footnotes | +513,067 | - | - | 8,974,061 | 12 d ago |
| Sep 28, 2026 | CConversion Common Stockindirect: See footnotes | +256,448 | - | - | 9,230,509 | 12 d ago |
| Sep 28, 2026 | POpen-market purchase Common Stockindirect: See footnotes | +61,516 | $17.00 | $1.0M | 9,292,025 | 12 d ago |
| Sep 28, 2026 | POpen-market purchase Common Stockindirect: See footnotes | +588,235 | $17.00 | $10.0M | 588,235 | 12 d ago |
| Sep 28, 2026 | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -10,690,530 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -2,000,962 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | CConversion Series B-1 Preferred Stockderivativeindirect: See footnotes | -769,601 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -564,187 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -7,127,019 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -1,333,975 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | CConversion Series B-1 Preferred Stockderivativeindirect: See footnotes | -513,067 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -256,448 | $0.00 | $0 | 0 | 12 d ago |
Related signals
Other insiders at ADARx Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 58Moderate | ADARx Pharmaceuticals, Inc. | Carl L Gordon director, owner | $16M 950,000 shares | +7% | |
| 50Moderate | ADARx Pharmaceuticals, Inc. | Erez Chimovits director | $1.0M 61,516 shares | +1% | |
| 61Notable | ADARx Pharmaceuticals, Inc. | Simeon George director, owner | $27M 1,600,000 shares | +32% | |
| 53Moderate | ADARx Pharmaceuticals, Inc. | Sr One Capital Management, LLC owner | $27M 1,600,000 shares | +32% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.